Compare
Northwest Biotherapeutics Inc vs Cannapharmarx, Inc. vs NRX Pharmaceuticals, Inc. vs IGC Pharma, Inc.
| Latest fiscal year | Northwest Biotherapeutics Inc NWBO | Cannapharmarx, Inc. CPMD | NRX Pharmaceuticals, Inc. NRXP | IGC Pharma, Inc. IGC |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-03-31 |
| Revenue | $1.38M | $1.36M | $1.45M | $1.27M |
| Revenue growth (YoY) | -0.3% | +66.1% | n/a | -5.5% |
| Gross margin | n/a | -153.1% | 65.1% (computed) | 48.7% |
| Operating margin | n/m | -245.8% | n/m | -585.8% |
| Net margin | n/m | -817.2% | n/m | -560.3% |
| Net income | -$60.16M | -$11.13M | -$28.62M | -$7.12M |
| EPS (Diluted) | -$0.04 | -$0.02 | n/a | -$0.09 |
| Operating cash flow | -$44.76M | -$789.1K | -$14.11M | -$4.79M |
| Free cash flow | -$46.27M | -$794.6K | n/a | -$4.91M |
| Cash & equivalents | $3.04M | $1.8K | $7.80M | $405.0K |
| Total assets | $81.29M | $7.02M | $12.96M | $8.75M |
| Total liabilities | $128.86M | $37.17M | $28.89M | $2.42M |
| Shareholders' equity | -$60.28M | -$30.15M | -$15.94M | $6.33M |
| Return on year-end equity | n/a | n/a | n/a | -112.5% |
| Shares outstanding | 1.56B | 662.50M | 31.73M | 80.88M |
Revenue, most recent five fiscal years
| Fiscal year | Northwest Biotherapeutics Inc | Cannapharmarx, Inc. | NRX Pharmaceuticals, Inc. | IGC Pharma, Inc. |
|---|---|---|---|---|
| Latest | $1.38M Ended 2025-12-31 | $1.36M Ended 2025-12-31 | $1.45M Ended 2025-12-31 | $1.27M Ended 2025-03-31 |
| 1 year earlier | $1.38M Ended 2024-12-31 | $820.1K Ended 2024-12-31 | $0 Ended 2024-12-31 | $1.34M Ended 2024-03-31 |
| 2 years earlier | $1.93M Ended 2023-12-31 | $0 Ended 2023-12-31 | $0 Ended 2023-12-31 | $911.0K Ended 2023-03-31 |
| 3 years earlier | $1.68M Ended 2022-12-31 | $0 Ended 2022-12-31 | n/a | $397.0K Ended 2022-03-31 |
| 4 years earlier | $1.00M Ended 2021-12-31 | $0 Ended 2021-12-31 | n/a | $898.0K Ended 2021-03-31 |